Global Cord Blood (NYSE:CO) Earns Strong-Buy Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Global Cord Blood (NYSE:CO) in a research note published on Sunday. The brokerage issued a strong-buy rating on the medical research company’s stock.

Global Cord Blood Trading Up 14.9 %

CO opened at $1.16 on Friday. The stock has a market capitalization of $141.00 million, a P/E ratio of 1.81 and a beta of 0.16. Global Cord Blood has a 12-month low of $2.03 and a 12-month high of $5.50. The stock has a 50-day moving average price of $1.14 and a 200-day moving average price of $1.38.

Global Cord Blood Company Profile

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.